<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2024-17-3-74-78</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1552</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Применение нового способа лечения персистирующих дефектов роговицы различного генеза</article-title><trans-title-group xml:lang="en"><trans-title>Usage of a new method of treatment of persistent corneal defects of various genesis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ченцова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chentsova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ченцова Екатерина Валериановна — д-р мед. наук, профессор, старший научный сотрудник отдела травматологии и реконструктивной хирургии.</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Ekaterina V. Chentsova — Dr. of Med. Sci., professor, senior researcher of the department of traumatology and reconstructive surgery.</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8897-7523</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боровкова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borovkova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Боровкова Наталья Валерьевна — д-р мед. наук, заведующая отделением биотехнологий и трансфузиологии.</p><p>Большая Сухаревская площадь, д. 3, Москва, 129090</p></bio><bio xml:lang="en"><p>Natalia V. Borovkova — Dr. of Med. Sci., head of the department of biotechnology and transfusiology.</p><p>Bolshaya Sukharevskaya Square, 3, Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-8147-186X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боженко</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bozhenko</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Боженко Дмитрий Андреевич — аспирант, врач-офтальмолог.</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Dmitry A. Bozhenko — PhD student, ophthalmologist.</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><email xlink:type="simple">panacelium@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономарев</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomarev</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пономарев Иван Николаевич — канд. мед. наук, старший научный сотрудник.</p><p>Большая Сухаревская площадь, д. 3, Москва, 129090</p></bio><bio xml:lang="en"><p>Ivan N. Ponomarev — Cand. of Med. Sci., senior researcher of the department of biotechnology and transfusiology.</p><p>Bolshaya Sukharevskaya Square, 3, Moscow, 129090</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макаров</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макаров Павел Васильевич — д-р мед. наук, ведущий научный сотрудник.</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Pavel V. Makarov — Dr. of Med. Sci., professor, leading researcher of the department of traumatology and reconstructive surgery.</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.V. Sklifosovsky Research Institute for Emergency Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2024</year></pub-date><volume>17</volume><issue>3</issue><fpage>74</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ченцова Е.В., Боровкова Н.В., Боженко Д.А., Пономарев И.Н., Макаров П.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ченцова Е.В., Боровкова Н.В., Боженко Д.А., Пономарев И.Н., Макаров П.В.</copyright-holder><copyright-holder xml:lang="en">Chentsova E.V., Borovkova N.V., Bozhenko D.A., Ponomarev I.N., Makarov P.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1552">https://roj.igb.ru/jour/article/view/1552</self-uri><abstract><p>Цель работы — сравнить эффективность применения обычного консервированного амниона и амниона, насыщенного лизатом богатой тромбоцитами плазмы (БоТП), для лечения эрозий после ожогов роговицы II–III степени и язв после кератитов. Материал и методы. Для сравнения эффективности консервированного амниона и пропитанного лизатом БоТП выделены 2 группы пациентов: основная (амнион, насыщенный лизатом БоТП) и группа сравнения (амнион без лизата БоТП). Использовали покрытие роговицы амниотической мембраной на 7–14 дней, после чего амнион удаляли и проводили контроль состояния роговицы. В каждую группу вошли пациенты с эрозиями после свежих ожогов площадью в среднем 60 % роговицы и язвами после кератитов с толщиной роговицы на дне язвы в среднем 382 мкм в опытной группе и 393 мкм в группе сравнения. Лизат БоТП изготавливали из аутологичной крови пациентов в лаборатории трансплантации клеток и иммунотипирования НИИ скорой помощи им. Н.В. Склифосовского по запатентованной технологии. Для этого из крови доноров выделяли БоТП с содержанием тромбоцитов свыше 1000 тыс/мкл, которую затем замораживали при -80 °С и размораживали при 0–4 °С с целью разрушения клеточных мембран для получения лизата. Результаты. Использование амниотической мембраны, насыщенной лизатом БоТП, приводило к эпителизации эрозий после свежих ожогов за 1,3 мес и уменьшению отека роговицы в среднем на 247 мкм, эпителизации язв после кератитов за 1,3 мес и увеличению толщины роговицы на дне язвы на 62,5 мкм. Лечение с помощью обычного консервированного амниона занимало 1,8 мес до полной эпителизации при свежих ожогах с уменьшением отека стромы роговицы на 193 мкм, а эпителизация язв после кератитов требовала 1,6 мес и заканчивалась увеличением толщины роговицы в месте язвы на 42 мкм. Заключение. Представленный метод лечения эрозий и язв роговицы различного генеза с использованием амниотической мембраны, насыщенной лизатом аутологичной БоТП, позволяет достичь полной и стойкой эпителизации в более короткие сроки и с меньшим количеством покрытий амнионом, чем в группе сравнения. При этом пациентам не требуется дополнительное консервативное лечение эпителиопатий.</p></abstract><trans-abstract xml:lang="en"><p>Purpose. The aim of the work is to compare the time of epithelization and the change in the thickness of the cornea in the treatment of erosions after corneal burns of 2–3 degrees and ulcers after keratitis with preserved amnion and amnion saturated with autologous PRP lysate. Materials and methods. To compare the effectiveness of preserved amnion and lysate-soaked PRP, 2 groups of patients were identified: the main group (amnion saturated with lysate PRP) and the comparison group (amnion without lysate PRP). Each group included patients with erosions after recent burns with an average area of 60 % of the cornea and ulcers after keratitis with a corneal thickness at the bottom of the ulcer of 382 microns in the experimental group and 393 microns in the comparison group. In the comparison group, ulcers were treated by covering the cornea with an amniotic membrane for 7–14 days, after which the amnion was removed and the condition of the cornea was monitored. An amniotic membrane saturated with PRP lysate was used in the experimental group. PRP lysate was made from autologous blood of patients in the laboratory of cell transplantation and immunotyping of the N.V. Sklifosovsky Research Institute of Emergency Medicine using a patented technology. To do this, platelet-rich plasma (PRP) with a platelet content of over 1000 thousand/ml was isolated from the blood of donors, which was then frozen at -80 °C and thawed at 0–4 °C in order to destroy cell membranes. Assessment of the condition of the cornea was carried out using clinical and instrumental studies, including biomicroscopy with fluorescein staining, photoregistration and OCT on the Heidelberg Engineering “OCT Spectralis” apparatus. Results. The use of an amniotic membrane saturated with PRP lysate led to epithelialization of erosions after recent burns in 1.3 months and a decrease in corneal edema by 247 microns, epithelialization of ulcers after keratitis in 1.3 months and an increase in the thickness of the cornea at the bottom of the ulcer by 62.5 microns. Treatment with conventional preserved amnion took 1.8 months before complete epithelization in recent burns with a decrease in corneal stroma edema by 193 microns, and epithelization of ulcers after keratitis required 1.6 months and ended with an increase in the thickness of the cornea at the site of the ulcer by 42 microns. Conclusion. The study showed that the presented method of treating erosions and ulcers of the cornea of various genesis using an amniotic membrane saturated with autologous PRP lysate allows achieving complete and persistent epithelialization in a shorter time and with fewer amnion coatings, unlike the comparison group. At the same time, patients do not need additional conservative treatment of epitheliopathies.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>амнион</kwd><kwd>богатая тромбоцитами плазма</kwd><kwd>эрозии роговицы</kwd><kwd>язвы роговицы</kwd><kwd>ожоги глаз</kwd><kwd>лизат тромбоцитов</kwd><kwd>ростстимулирующий эффект</kwd></kwd-group><kwd-group xml:lang="en"><kwd>amnion</kwd><kwd>platelet-rich plasma</kwd><kwd>corneal erosion</kwd><kwd>corneal ulcers</kwd><kwd>eye burns</kwd><kwd>platelet lysate</kwd><kwd>growth-stimulating effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years: evaluating the prevalence of avoidable blindness in relation to “VISION 2020: the Right to Sight”. Lancet Global Health 2020. doi.org/10.1016/S2214-109X(20)30489-7</mixed-citation><mixed-citation xml:lang="en">Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years: evaluating the prevalence of avoidable blindness in relation to “VISION 2020: the Right to Sight”. Lancet Global Health 2020. doi.org/10.1016/S2214-109X(20)30489-7</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Куликов А.Н., Чурашов С.В., Черныш В.Ф. и др. Современные подходы к проблеме выбора носителя для культивирования стволовых клеток роговицы в лечении лимбальной недостаточности. Офтальмологические ведомости. 2018; 11 (2): 48–56. doi: 10.17816/OV11248-56</mixed-citation><mixed-citation xml:lang="en">Kulikov A.N., Churashov S.V., Chernysh V.F., et al. Modern approaches to the problem of choosing a carrier for the cultivation of corneal stem cells in the treatment of limbal insufficiency. Ophthalmological statements. 2018; 11 (2): 48–56 (In Russ.). doi: 10.17816/OV11248-56</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cabral JV, Jackson CJ, Utheim TP, Jirsova K. Ex vivo cultivated oral mucosal epithelial cell transplantation for limbal stem cell deficiency: a review. Stem Cell Res Ther. 2020;11(1):301. doi: 10.1186/s13287-020-01783-8</mixed-citation><mixed-citation xml:lang="en">Cabral JV, Jackson CJ, Utheim TP, Jirsova K. Ex vivo cultivated oral mucosal epithelial cell transplantation for limbal stem cell deficiency: a review. Stem Cell Res Ther. 2020;11(1):301. doi: 10.1186/s13287-020-01783-8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Шевлюк Н.Н., Гатиатуллин И.З., Стадников А.А. Особенности репаративных гистогенезов при использовании биопластических материалов. Журнал анатомии и гистопатологии. 2020; 9 (1): 86–93. doi: 10.18499/2225-7357-2020-9-1-86-93</mixed-citation><mixed-citation xml:lang="en">Shevlyuk N.N., Gatiatullin I.Z., Stadnikov A.A. Features of reparative histogenesis using bioplastic materials. Journal of Anatomy and Histopathology. 2020; 9 (1): 86–93 (In Russ.). doi: 10.18499/2225-7357-2020-9-1-86-93</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nejad AR, Hamidieh AA, Amirkhani MA, Sisakht MM. Update review on five top clinical applications of human amniotic membrane in regenerative medicine. Placenta. 2021; 103: 104–19. doi: 10.1016/j.placenta.2020.10.026</mixed-citation><mixed-citation xml:lang="en">Nejad AR, Hamidieh AA, Amirkhani MA, Sisakht MM. Update review on five top clinical applications of human amniotic membrane in regenerative medicine. Placenta. 2021; 103: 104–19. doi: 10.1016/j.placenta.2020.10.026</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cirman T, Beltram M, Schollmayer P, Rožman P, Kreft ME. Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia. Cell and Tissue Banking. 2013; 15 (2): 177–92. doi: 10.1007/s10561-013-9417-6</mixed-citation><mixed-citation xml:lang="en">Cirman T, Beltram M, Schollmayer P, Rožman P, Kreft ME. Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia. Cell and Tissue Banking. 2013; 15 (2): 177–92. doi: 10.1007/s10561-013-9417-6</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">McDaniel JS, Wehmeyer JL, Cornell LE, Johnson AJ, Zamora DO. Amniotic membrane allografts maintain key biological properties post SCCO2 and lyophilization processing. J Biomater Appl. 2021; 35 (6): 592–601. doi: 10.1177/0885328220952585</mixed-citation><mixed-citation xml:lang="en">McDaniel JS, Wehmeyer JL, Cornell LE, Johnson AJ, Zamora DO. Amniotic membrane allografts maintain key biological properties post SCCO2 and lyophilization processing. J Biomater Appl. 2021; 35 (6): 592–601. doi: 10.1177/0885328220952585</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Le Q, Deng SX. The application of human amniotic membrane in the surgical management of limbal stem cell deficiency. Ocul Surf. 2019; 17 (2): 221–9. doi: 10.1016/j.jtos.2019.01.003</mixed-citation><mixed-citation xml:lang="en">Le Q, Deng SX. The application of human amniotic membrane in the surgical management of limbal stem cell deficiency. Ocul Surf. 2019; 17 (2): 221–9. doi: 10.1016/j.jtos.2019.01.003</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Борзенок С.А., Ролик О.И., Онищенко Н.А., Комах Ю.А. О возможности совершенствования консервации донорских роговиц путем применения регуляторных пептидов. Вестник трансплантологии и искусственных органов. 2011; 13 (4): 101–5. doi:10.15825/1995-1191-2011-4-101-105</mixed-citation><mixed-citation xml:lang="en">Borzenok S.A., Roller O.I., Onishchenko N.A., Komakh Yu.A. On the possibility of improving the preservation of donor corneas by using regulatory peptides. Bulletin of Transplantology and Artificial Organs. 2011; 13 (4): 101–5 (In Russ.). doi:10.15825/1995-1191-2011-4-101-105</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Walkden A. Amniotic membrane transplantation in ophthalmology: An updated perspective. Clin Ophthalmol. 2020 Jul 22; 14: 2057–72. doi: 10.2147/OPTH.S208008</mixed-citation><mixed-citation xml:lang="en">Walkden A. Amniotic membrane transplantation in ophthalmology: An updated perspective. Clin Ophthalmol. 2020 Jul 22; 14: 2057–72. doi: 10.2147/OPTH.S208008</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013; (4): 67. doi: 10.1186/scrt218</mixed-citation><mixed-citation xml:lang="en">Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013; (4): 67. doi: 10.1186/scrt218</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021; 14 (1): 97–108. doi: 10.1080/17474086.2021.1860002</mixed-citation><mixed-citation xml:lang="en">Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021; 14 (1): 97–108. doi: 10.1080/17474086.2021.1860002</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Макаров М.С., Сторожева М.В., Конюшко О.И., Боровкова Н.В., Хватов В.Б. Влияние концентрации тромбоцитарного фактора роста на пролиферативную активность фибробластов человека. Клеточные технологии в биологии и медицине. 2013; (2): 111–5. doi: 10.1007/s10517-013-2199-9</mixed-citation><mixed-citation xml:lang="en">Makarov M.S., Storozheva M.V., Konyushko O.I., Borovkova N.V., Khvatov V.B. Influence of platelet growth factor concentration on proliferative activity of human fibroblasts. Cell technologies in biology and medicine. 2013; (2): 111–5 (In Russ.). doi: 10.1007/s10517-013-2199-9</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Боровкова Н.В., Макаров М.С., Андреев Ю.В., Сторожева М.В., Пономарев И.Н. Оценка цитокинового состава сыворотки крови и препаратов на основе тромбоцитов человека. Молекулярная медицина. 2021; 19 (3): 51–7. doi: 10.29296/24999490-2021-03-08</mixed-citation><mixed-citation xml:lang="en">Borovkova N.V., Makarov M.S., Andreev Yu.V., Storozheva M.V., Ponomarev I.N. Evaluation of the cytokine composition of blood serum and preparations based on human platelets. Molecular medicine. 2021; 19 (3): 51–7 (In Russ.). doi: 10.29296/24999490-2021-03-08</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Боровкова Н.В., Макаров М.С., Сторожева М.В., Пономарев И.Н. Способ приготовления лизата тромбоцитов с высоким содержанием факторов роста. Патент РФ на изобретение № 2739515C1 от 25.12.2020.</mixed-citation><mixed-citation xml:lang="en">Borovkova N.V., Makarov M.S., Storozheva M.V., Ponomarev I.N. Method of preparation of platelet lysate with a high content of growth factors. Patent RU №2739515C1, 25.12.2020 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ченцова Е.В., Боровкова Н.В., Боженко Д.А. и др. Способ хирургического лечения дефектов роговицы различного генеза. Патент РФ на изобретение № 2782129, 2022.</mixed-citation><mixed-citation xml:lang="en">Chentsova E.V., Borovkova N.V., Bozhenko D.A., et al. Method of surgical treatment of corneal defects of various genesis. Patent RU No. 2782129, 2022 (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
